4 Einträge gefunden

1. JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis

   1. Stübig, T
   2. Alchalby, H
   3. Ditschkowski, M
   4. Wolf, D
   5. Wulf, G
   6. Zabelina, T
   7. Wolschke, C

   2014 - Forschungsinformationssystem des UKE
2. Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients.

   1. Kröger, N
   2. Zabelina, T
   3. Klyuchnikov, E
   4. Kropff, M
   5. Pflüger, K-H
   6. Burchert, A
   7. Stübig, T

   2013 - Forschungsinformationssystem des UKE
3. Donor choice according to age for allo-SCT for AML in complete remission

   1. Ayuketang, Francis Ayuk
   2. Zabelina, T
   3. Wortmann, F
   4. Alchalby, H
   5. Wolschke, C
   6. Lellek, H
   7. Bacher, U

   2013 - Forschungsinformationssystem des UKE
4. Impact of physiological BM CD10+CD19+ B-cell precursors (haematogones) in the post-transplant period in patients with AML

   1. Christopeit, Maximilian
   2. Heiland, A
   3. Binder, M
   4. Zabelina, T
   5. Ayuketang, Francis Ayuk
   6. Horn, C
   7. Haferlach, T

   2013 - Forschungsinformationssystem des UKE